LQDA supply chain intelligence for Liquidia Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LGM-PHARMA-LLC | LGM-PHARMA-LLC | 92% | we currently rely on a sole supplier, LGM Pharma, LLC ("LGM"), for treprostinil, the active pharmaceutical ingredient of YUTREPIA |
| LONZA-TAMPA-LLC | LONZA-TAMPA-LLC | 92% | we also rely on a sole supplier, Lonza Tampa LLC ("Lonza"), for encapsulation and packaging services for YUTREPIA |
| PLASTIAPE-S-P-A | PLASTIAPE-S-P-A | 92% | we currently rely on a sole supplier, Plastiape S.p.A ("Plastiape"), for RS00 Model DPI, the device used to administer YUTREPIA |
| GILD | Gilead Sciences, Inc. | 72% | perational fabrication lines are scaled and capable of producing the necessary materials to support our clinical trials and, if approved, initial commercial demand for YUTREPIA. In August 2021, the F… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from GILD graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from GILD g… |
| GOSS | Gossamer Bio, Inc. | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| GOSS | Gossamer Bio, Inc. | 72% | Reciprocal relationship from GOSS graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injectio… |
| GSK | GSK plc | 72% | perational fabrication lines are scaled and capable of producing the necessary materials to support our clinical trials and, if approved, initial commercial demand for YUTREPIA. In August 2021, the F… |
| GSK | GSK plc | 72% | Reciprocal relationship from GSK graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from GSK graph: Reciprocal relationship from LQDA graph: perational fabrication lines are scal… |
| JNJ | Johnson & Johnson | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection… |
| NVSEF | Novartis AG | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injecti… |
| ORANY | ORANY | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injecti… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| GOSS | Gossamer Bio, Inc. | 72% | Reciprocal relationship from GOSS graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injectio… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability t… |
| JNJ | Johnson & Johnson | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| NVSEF | Novartis AG | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injecti… |
| ORANY | ORANY | 72% | -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injecti… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LQDA-DEBT-10789 | Warrants outstanding: 1317000 | 90% | xbrl warrant detail from xbrl 2022-12-31. |
| LQDA-DEBT | Debt stack $184.8M | 90% | Market cache reports total debt of $184.8M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| LQDA-OWNER-FARALLON-CAPITAL-MANAGEMENT-LLC | FARALLON CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists FARALLON CAPITAL MANAGEMENT LLC as top holder; 253 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALC | Alcon Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| SNNUF | Smith & Nephew plc | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| SLGL | Sol-Gel Technologies Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 |